Impact of dosing schedules on performance of rotavirus vaccines in Ghana.
| Autor: | Asare EO; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.; Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT, USA., Al-Mamun MA; Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA., Armah GE; Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana., Lopman BA; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Pitzer VE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.; Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Science advances [Sci Adv] 2024 Dec 13; Vol. 10 (50), pp. eadn4176. Date of Electronic Publication: 2024 Dec 11. |
| DOI: | 10.1126/sciadv.adn4176 |
| Abstrakt: | There is currently limited evidence regarding how the rotavirus vaccine dosing schedule might be adjusted to improve vaccine performance. We quantified the impact of the previously implemented 6/10-week Rotarix vaccine (RV1) in Ghana to the model-predicted impact for other vaccine dosing schedules across three hospitals and the entire country. Compared to no vaccination, the model-estimated median percentage reductions in rotavirus ranged from 28 to 85% and 12 to 71% among children <1 and <5 years old, respectively. The median predicted reductions in rotavirus for the whole country ranged from 57 to 66% among infants <1 year and 35 to 45% among children <5 years old. The 1/6/10- and 6/10/14-week schedules provided the best and comparable reductions in rotavirus compared to the original 6/10-week schedule. A third dose could prevent an additional 9 to 14% of deaths. An additional dose of RV1 might be an effective strategy to improve rotavirus vaccine impact, particularly in settings with low vaccine effectiveness. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|